Terms: = Leukemia AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck
226 results:
1. Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting lck in acute lymphoblastic leukemia.
Chen Y; Zhang K; Tan J; Fan Z; Fu Y; Li X; Liu B; Wang G
Bioorg Chem; 2024 Mar; 144():107180. PubMed ID: 38335758
[TBL] [Abstract] [Full Text] [Related]
2. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic leukemia.
Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
[TBL] [Abstract] [Full Text] [Related]
4. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Harrington P; Dillon R; Radia D; Rousselot P; McLornan DP; Ong M; Green A; Verde A; Hussain F; Raj K; Kordasti S; Harrison C; De Lavallade H
Haematologica; 2023 Jun; 108(6):1555-1566. PubMed ID: 36700403
[TBL] [Abstract] [Full Text] [Related]
5. ArtinM Cytotoxicity in B Cells Derived from Non-Hodgkin's Lymphoma Depends on Syk and Src Family Kinases.
Barboza BR; Thomaz SMO; Junior AC; Espreafico EM; Miyamoto JG; Tashima AK; Camacho MF; Zelanis A; Roque-Barreira MC; da Silva TA
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674590
[TBL] [Abstract] [Full Text] [Related]
6. Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia.
Jin Q; Gutierrez Diaz B; Pieters T; Zhou Y; Narang S; Fijalkwoski I; Borin C; Van Laere J; Payton M; Cho BK; Han C; Sun L; Serafin V; Yacu G; Von Loocke W; Basso G; Veltri G; Dreveny I; Ben-Sahra I; Goo YA; Safgren SL; Tsai YC; Bornhauser B; Suraneni PK; Gaspar-Maia A; Kandela I; Van Vlierberghe P; Crispino JD; Tsirigos A; Ntziachristos P
Sci Adv; 2022 Dec; 8(49):eabq8437. PubMed ID: 36490346
[TBL] [Abstract] [Full Text] [Related]
7. A Cysteine Residue within the Kinase Domain of Zap70 Regulates lck Activity and Proximal TCR Signaling.
Schultz A; Schnurra M; El-Bizri A; Woessner NM; Hartmann S; Hartig R; Minguet S; Schraven B; Simeoni L
Cells; 2022 Sep; 11(17):. PubMed ID: 36078131
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical evaluation of proteolytic targeting of lck as a therapeutic approach in T cell acute lymphoblastic leukemia.
Hu J; Jarusiewicz J; Du G; Nishiguchi G; Yoshimura S; Panetta JC; Li Z; Min J; Yang L; Chepyala D; Actis M; Reyes N; Smart B; Pui CH; Teachey DT; Rankovic Z; Yang JJ
Sci Transl Med; 2022 Aug; 14(659):eabo5228. PubMed ID: 36001679
[TBL] [Abstract] [Full Text] [Related]
9. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.
Fazio G; Bresolin S; Silvestri D; Quadri M; Saitta C; Vendramini E; Buldini B; Palmi C; Bardini M; Grioni A; Rigamonti S; Galbiati M; Mecca S; Savino AM; Peloso A; Tu JW; Bhatia S; Borkhardt A; Micalizzi C; Lo Nigro L; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Te Kronnie G; Biondi A; Cazzaniga G
EBioMedicine; 2022 Sep; 83():104224. PubMed ID: 35985167
[TBL] [Abstract] [Full Text] [Related]
10. Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic leukemia Cell Lines.
Perbellini O; Cavallini C; Chignola R; Galasso M; Scupoli MT
Cells; 2022 Jun; 11(13):. PubMed ID: 35805156
[TBL] [Abstract] [Full Text] [Related]
11. Identification of RCC1-lck as a novel fusion gene in pediatric erythroid sarcoma.
Oya S; Osone S; Yoshida M; Nishimoto S; Taura Y; Yoshida H; Miyachi M; Inaba T; Konishi E; Kato M; Imamura T; Iehara T
Pediatr Blood Cancer; 2022 Sep; 69(9):e29848. PubMed ID: 35714314
[TBL] [Abstract] [Full Text] [Related]
12. BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.
Kauer J; Märklin M; Pflügler M; Hörner S; Hinterleitner C; Tandler C; Jung G; Salih HR; Heitmann JS
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2759-2771. PubMed ID: 35551463
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic targeting of lck tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract] [Full Text] [Related]
14. Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia.
He Y; Zhang J; Zhang Y; Hu Z; Wang P; Gan W; Xie S; Qian M; Pui CH; Jiang H; Zhu X; Zhang H; Zhang W
Pediatr Blood Cancer; 2022 Aug; 69(8):e29724. PubMed ID: 35441457
[TBL] [Abstract] [Full Text] [Related]
15. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic leukemia.
Braun T; Stachelscheid J; Bley N; Oberbeck S; Otte M; Müller TA; Wahnschaffe L; Glaß M; Ommer K; Franitza M; Gathof B; Altmüller J; Hallek M; Auguin D; Hüttelmaier S; Schrader A; Herling M
Cancer Res; 2022 May; 82(9):1818-1831. PubMed ID: 35259248
[TBL] [Abstract] [Full Text] [Related]
16. Adiponectin and Its Effects on Acute leukemia Cells: An Experimental and Bioinformatics Approach.
Tsartsalis AN; Tagka A; Kotoulas A; Mirkopoulou D; Geronikolou SA; G L
Adv Exp Med Biol; 2021; 1338():117-127. PubMed ID: 34973016
[TBL] [Abstract] [Full Text] [Related]
17. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
[TBL] [Abstract] [Full Text] [Related]
18. Network-based systems pharmacology reveals heterogeneity in lck and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
[TBL] [Abstract] [Full Text] [Related]
19. Expression and prognosis analyses of CASP1 in acute myeloid leukemia.
Liu J; Zhao M; Feng X; Zeng Y; Lin D
Aging (Albany NY); 2021 May; 13(10):14088-14108. PubMed ID: 33999861
[TBL] [Abstract] [Full Text] [Related]
20. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
[TBL] [Abstract] [Full Text] [Related]
[Next]
